Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 385 participants.

Also called NCT02451098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 385 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02451098
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02451098. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
Condition
Hyperlipidemia
Intervention (Drug)
Atorvastatin10mg, Ezetimibe10mg
Intervention (Drug)
Atorvastatin10mg, Ezetimibe placebo
Intervention (Drug)
Atorvastatin20mg, Ezetimibe10mg
Intervention (Drug)
Atorvastatin20mg, Ezetimibe placebo
Intervention (Drug)
Atorvastatin40mg, Ezetimibe10mg
Intervention (Drug)
Atorvastatin40mg, Ezetimibe placebo
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct02451098
Content hash
d1325935be8c5d75e6d1af2e4a810b9bfdb562f3f20eda965a702de73a27c9cc